ReviewNature reviews. Immunology2020
Enhancing cancer immunotherapy with nanomedicine.
Review in Nature reviews. Immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 331 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
331 citing papers in PubMed, 822 citations in OpenAlex.
- Polymersome-based nanomedicine for combined cancer therapy.Drug delivery · 2026Review
- Cancer nanomedicine and RNA/Lipid nanoparticle platforms in oncology: developmental evolution, translational barriers, and precision-therapy opportunities.Journal of the Egyptian National Cancer Institute · 2026Review
- Nanomedicine beyond carriers - devices, cells & living therapeutics.Biomedical microdevices · 2026Review
- Review
- Cold and hot tumors: immunological determinants, cancer-immunity cycle dysregulation, and nanotechnology-driven therapeutic approaches.Molecular biomedicine · 2026Review
- Nanoparticle Platforms in Cancer Immunotherapy: A Critical Comparative Review of PLGA, Mesoporous Silica, Magnetic Nanoparticles, and Covalent Organic Frameworks.Pharmaceutics · 2026Review
- Cell-Type-Tailored Hydrogels for Adoptive Cell Therapy in Cancer.Gels (Basel, Switzerland) · 2026Review
- Advances in improving cancer immunotherapy with nanotechnology: from smart nanoparticles to synergistic combination strategies.Molecular cancer · 2026Review
- Hydrogel-Nanoparticle Bioactive Platforms for Post-Surgical Prevention of Tumor Recurrence.Nanomaterials (Basel, Switzerland) · 2026Review
- A Comprehensive Review on CRISPR-Based Screening and Its Applications.Molecular biotechnology · 2026Review
- Guiding off-target nanomedicine repurposing in spleen for cancer immunotherapy.Journal of nanobiotechnology · 2026Article
- Smart Nanomaterials and Natural Biologics for Innate-Adaptive Immune Reprogramming: A Nanobiotechnology Framework for Translational Medicine.Nanomaterials (Basel, Switzerland) · 2026Review
- Nanomedicine in precision treatment of gastric cancer: current clinical landscape.Molecular biology reports · 2026Review
- A lymph node-targeted cell-nanoadjuvant conjugate enhances dendritic cell-T cell crosstalk for cancer immunotherapy.Acta pharmaceutica Sinica. B · 2026Article
- A HO-1 gene knockout using a NanoCRISPR scaffold suppresses metastasis in mouse models.Nature biomedical engineering · 2026Article
- Nanotechnology-Based Cancer Vaccines: Translational Barriers and Emerging Strategies.Vaccines · 2026Review
- Nanotechnology in Cancer Therapy: How Nanoparticles Are Shaping the Future of Personalized Treatment.ACS nano medicine · 2026Review
- Boosting immunogenic tumour cell death via nanotherapeutic targeting of the Stanniocalcin 1 phagocytosis checkpoint for enhanced cancer immunotherapy.Nature communications · 2026Article
- Programmed cell death in lung cancer: mechanisms, immune responses, and therapeutics.Apoptosis : an international journal on programmed cell death · 2026Review
- Nanomedicine in immunotherapy of urinary system tumors: advances, synergistic strategies, and translational challenges.Journal of nanobiotechnology · 2026Review
271 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Therapeutic targeting of the immune system in cancer is now a clinical reality and marked successes have been achieved, most notably through the use of checkpoint blockade antibodies and chimeric antigen receptor T cell therapy. However, efforts to develop new immunotherapy agents or combination treatments to increase the proportion of patients who benefit have met with challenges of limited efficacy and/or significant toxicity. Nanomedicines - therapeutics composed of or formulated in carrier materials typically smaller than 100 nm - were originally developed to increase the uptake of chemotherapy agents by tumours and to reduce their off-target toxicity. Here, we discuss how nanomedicine-based treatment strategies are well suited to immunotherapy on the basis of nanomaterials' ability to direct immunomodulators to tumours and lymphoid organs, to alter the way biologics engage with target immune cells and to accumulate in myeloid cells in tumours and systemic compartments. We also discuss early efforts towards clinical translation of nanomedicine-based immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.